|
gptkbp:instanceOf
|
gptkb:vaccine
|
|
gptkbp:administeredBy
|
adults 18 years and older
|
|
gptkbp:alsoKnownAs
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
gptkb:Vaxzevria
gptkb:Covishield
|
|
gptkbp:approvedBy
|
December 2020
over 180 countries
|
|
gptkbp:category
|
gptkb:COVID-19_vaccines
2020 introductions
AstraZeneca products
Viral vector vaccines
|
|
gptkbp:clinicalTrialPhase
|
conducted in UK, Brazil, South Africa
|
|
gptkbp:compatibleWith
|
United States (as of 2024)
|
|
gptkbp:contains
|
genetic material encoding SARS-CoV-2 spike protein
|
|
gptkbp:contraindication
|
severe allergic reaction to previous dose
known hypersensitivity to ingredients
|
|
gptkbp:developedBy
|
gptkb:University_of_Oxford
gptkb:AstraZeneca
gptkb:Serum_Institute_of_India
|
|
gptkbp:dosingSchedule
|
two doses, 4–12 weeks apart
|
|
gptkbp:effect
|
~70% (varies by study and dosing interval)
|
|
gptkbp:emergencyServices
|
gptkb:India
gptkb:World_Health_Organization
gptkb:UK_Medicines_and_Healthcare_products_Regulatory_Agency
gptkb:European_Medicines_Agency
|
|
gptkbp:mainIngredient
|
gptkb:L-histidine
gptkb:disodium_edetate_dihydrate
gptkb:polysorbate_80
sodium chloride
ethanol
sucrose
water for injections
magnesium chloride hexahydrate
L-histidine hydrochloride monohydrate
|
|
gptkbp:manufacturer
|
gptkb:SK_Bioscience
gptkb:AstraZeneca
gptkb:Serum_Institute_of_India
gptkb:R-Pharm
gptkb:Siam_Bioscience
gptkb:Fiocruz
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fatigue
headache
injection site pain
rare blood clotting events
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:trialSponsor
|
gptkb:Saudi_Arabian_government
gptkb:Ugandan_government
gptkb:Rwandan_government
gptkb:COVAX
gptkb:Colombian_government
gptkb:Gavi
gptkb:Qatari_government
gptkb:NIHR
gptkb:Chilean_government
gptkb:European_Parliament
gptkb:European_Union
gptkb:Government_of_India
gptkb:Parliament_of_the_United_Kingdom
gptkb:University_of_Oxford
gptkb:WHO
gptkb:Afghan_government
gptkb:Philippine_government
gptkb:Yemeni_government
gptkb:South_Korean_government
gptkb:Palestinian_government
gptkb:Omani_government
gptkb:UK_Research_and_Innovation
gptkb:Iranian_government
gptkb:Japanese_government
gptkb:Burundian_government
gptkb:Congolese_government
gptkb:CEPI
gptkb:AstraZeneca
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Indonesian_government
gptkb:Mexican
gptkb:Wellcome_Trust
gptkb:Turkish_government
gptkb:Vietnamese_government
gptkb:BARDA
gptkb:Zimbabwean_government
gptkb:Egyptian_government
gptkb:Namibian_government
gptkb:South_African_government
gptkb:Bahraini_government
gptkb:Kuwaiti_government
gptkb:Lebanese_government
gptkb:Malaysian_government
gptkb:Singaporean_government
gptkb:Pakistani_government
gptkb:Brazilian_government
gptkb:Kenyan_government
gptkb:Tanzanian_government
gptkb:Bangladeshi_government
gptkb:Syrian_government
gptkb:Angolan_government
gptkb:Sudanese_government
gptkb:Serum_Institute_of_India
gptkb:BARDA_(US)
gptkb:Botswanan_government
gptkb:National_Institutes_of_Health_(US)
gptkb:United_Arab_Emirates_government
gptkb:Ethiopian_government
gptkb:Jordanian_government
gptkb:Sri_Lankan_government
gptkb:Coalition_for_Epidemic_Preparedness_Innovations
gptkb:Mozambican_government
gptkb:Nepalese_government
Iraqi government
Argentinian government
|
|
gptkbp:type
|
gptkb:viral_vector_vaccine
|
|
gptkbp:vectorFor
|
gptkb:chimpanzee_adenovirus_(ChAdOx1)
|
|
gptkbp:WHO_EUL
|
February 2021
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca_COVID-19_vaccine
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AZD1222
|